Company Website:
http://www.regenerx.com
ROCKVILLE, Md. -- (Business Wire)
RegeneRx Biopharmaceuticals, Inc. (OTC: RGRX) (“the Company” or
“RegeneRx”) today announced that it has received a Notice of Allowance
of a Chinese patent application for uses of Thymosin beta 4 (TB4) for
treating, preventing, inhibiting or reducing heart tissue deterioration,
injury or damage in a subject with heart failure disease. Claims also
include uses for restoring heart tissue in those subjects. The patent
will expire July 26, 2026.
About RegeneRx Biopharmaceuticals, Inc. (www.regenerx.com)
RegeneRx is focused on the development of a novel therapeutic peptide,
Thymosin beta 4, for tissue and organ protection, repair and
regeneration. RegeneRx currently has three drug candidates in clinical
development for ophthalmic, cardiac and dermal indications, two
strategic licensing agreements in China and the EU, and has an extensive
worldwide patent portfolio covering its products.
Forward-Looking Statements
Any statements in this press release that are not historical facts are
forward-looking statements made under the provisions of the Private
Securities Litigation Reform Act of 1995. Any forward-looking statements
involve risks and uncertainties that could cause actual results to be
materially different from historical results or from any future results
expressed or implied by such forward-looking statements. Please view
these and other risks described in the Company’s filings with the
Securities and Exchange Commission (“SEC”), including those identified
in the “Risk Factors” section of the annual report on Form 10-K for the
year ended December 31, 2011, and subsequent quarterly reports filed on
Form 10-Q, as well as other filings it makes with the SEC. Any
forward-looking statements in this press release represent the Company’s
views only as of the date of this release and should not be relied upon
as representing its views as of any subsequent date. The Company
specifically disclaims any obligation to update this information, as a
result of future events or otherwise, except as required by applicable
law.
Contacts:
For RegeneRx:
Lori Smith, 301-208-9191
las@regenerx.com
Source: RegeneRx Biopharmaceuticals, Inc.